Medtronic InSync III
This article was originally published in The Gray Sheet
Executive Summary
Latest version of the implantable heart failure pacing system for resynchronization therapy is approved by FDA, adding a "sequential bi-ventricular pacing" function and advanced patient monitoring capabilities to the original InSync pacer, approved in August 2001. The new system allows physicians to "independently program and control the sequence of contractions of the right and left sides of the heart" to improve heart performance, according to Medtronic. InSync III has been available in Europe and Canada since June 2001...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.